-
Article
Author Correction: An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis
-
Article
An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis
As a chronic autoinflammatory condition, ulcerative colitis is often managed via systemic immunosuppressants. Here we show, in three mouse models of established ulcerative colitis, that a subcutaneously inject...
-
Article
Open AccessGenitourinary cancers updates: highlights from ASCO 2023
Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight ...
-
Article
Open AccessOutcomes of surgical resection and intraoperative electron radiotherapy for patients with para-aortic recurrences of gastrointestinal and gynecologic malignancies
Para-aortic lymph node (PALN) metastases from primary pelvic malignancies are often treated with resection, but recurrence is common. We report toxicity and oncologic outcomes for patients with PALN metastases...
-
Article
Author Correction: Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
A Correction to this paper has been published: https://doi.org/10.1038/s41565-021-00864-w.
-
Article
Open AccessCOVID-19 vaccines for patients with cancer: benefits likely outweigh risks
Less than a year since the start of the COVID-19 pandemic, ten vaccines against SARS-CoV-2 have been approved for at least limited use, with over sixty others in clinical trials. This swift achievement has gen...
-
Article
Dosimetric correlations with urinary quality of life in patients receiving post-prostatectomy radiation therapy
Acute urinary toxicity is well-documented in individuals receiving post-prostatectomy radiation. However, dosimetric correlations between bladder dose and acute urinary symptoms in the post-prostatectomy setti...
-
Article
Open AccessHarnessing nanomedicine to overcome the immunosuppressive tumor microenvironment
Cancer immunotherapy has received extensive attention due to its ability to activate the innate or adaptive immune systems of patients to combat tumors. Despite a few clinical successes, further endeavors are ...
-
Article
Open AccessProstate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
Intermittent androgen deprivation therapy (IADT) is an attractive treatment for biochemically recurrent prostate cancer (PCa), whereby cycling treatment on and off can reduce cumulative dose and limit toxiciti...
-
Article
Leptin ameliorates the immunity, but not reproduction, trade-off with endurance in lizards
Life-history trade-offs result from allocation of limited energetic resources to particular traits at the expense of others. When resources are scarce, some traits will take priority over others in the degree ...
-
Chapter
Cancer Nanotherapeutics Administered by Non-conventional Routes
Nanoparticle drug formulations (NDFs) allow for local and durable release of cancer therapeutics, and hold tremendous promise for advancing the efficacy of cancer treatment strategies. NDFs can be administered...
-
Article
Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds
Metastatic disease remains the primary cause of mortality in cancer patients. Yet the number of available in vitro models to study metastasis is limited by challenges in the recapitulation of the metastatic mi...
-
Article
Open AccessFitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy
To estimate the radiobiological parameters of three popular normal tissue complication probability (NTCP) models, which describe the dose-response relations of bladder regarding different acute urinary symptom...
-
Chapter
Pancreas Cancer
The use of RT for pancreatic cancer is controversial. Though RT increases local control, this has not usually translated to an OS benefit, likely due to the high competing risk of distant metastases. Selection...
-
Chapter
Rectal Cancer
For locally advanced (e.g., T3 or N+) rectal cancer, RT is conventionally delivered with concurrent chemotherapy over a course of 5–6 weeks, 4–8 weeks before or after surgery. However, numerous randomized tria...
-
Chapter
Hepatobiliary Malignancies
Historically, the radiosensitivity of hepatocytes and risk for radiation-induced liver disease (RILD) precluded the use of RT for liver tumors using older techniques. CT-based planning, SBRT, and IMRT have gen...
-
Article
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Nanoparticles can be utilized to capture tumour antigens and improve their presentation, which in turn improves the efficacy of cancer immunotherapy.
-
Article
Open AccessApplication of nanotechnology to cancer radiotherapy
Radiotherapy has been an integral treatment modality for cancer. The field arose from and progressed through innovations in physics, engineering, and biology. The evolution of radiation oncology will rely on t...
-
Chapter
Nanoparticles for Cancer Diagnosis and Therapy
Nanotechnology enables unique approaches to the diagnosis and treatment of cancer. Over the last two decades, a large number of nanoparticle-based cancer diagnostics and therapeutics have been developed. These...
